PDS0102 is a novel investigational T cell receptor gamma alternate reading frame protein (TARP)-targeted immunotherapy that stimulates a potent targeted T cell attack against TARP-positive cancers. PDS0102 is given by a simple subcutaneous injection alone or in combination with other immunotherapies and cancer treatments. Preclinical data suggests PDS0102 generates clinically effective immune responses, and demonstrates significant disease control by shrinking tumors, delaying disease progression and/or prolonging survival. PDS0102 combines the utility of the Versamune® platform with this proprietary TARP antigen developed by the National Cancer Institute (NCI).
Approximately 450,000 patients are diagnosed with acute myeloid leukemia (AML), prostate or breast cancer each year, most of which are associated with TARP. TARP-positive cancers that overexpress the immunogenic TARP protein such as prostate and breast cancer can be identified through tissue examination or biopsy and imaging (CT, PET X-ray, MRI). Currently TARP-positive cancers are treated with surgery, chemotherapy, radiation and immunotherapies either alone or in combination. There remains a high unmet need for more effective, safer, better tolerated and TARP-targeted treatment options
PDS0102 is currently in late-stage pre-clinical development.